Appointment of Jacobo Sellarés
Every person with a lung disease asks us a question; our job is to turn it into knowledge that changes how we treat it

Current research

Problem

Severe lung diseases can begin with an acute injury, such as pneumonia or respiratory failure, or with chronic inflammation, such as sarcoidosis. Some cases resolve, but in others the damage persists and progresses to pulmonary fibrosis, an irreversible scarring process that reduces both quality of life and life expectancy. Currently, we are unable to predict which patients will experience poor outcomes or which treatments will work best for them, meaning that many receive therapy too late or are given treatments that ultimately prove ineffective.

Approach

We study the host response to lung injury in large patient cohorts from Hospital Clínic and national and European networks. We combine clinical data, quantitative imaging powered by artificial intelligence, multi-omics approaches (transcriptomics, immune phenotyping, microbiome analysis, and blood biomarkers), and experimental models to identify the mechanisms that determine whether lung damage is repaired or progresses to chronic disease. We integrate this information using bioinformatics and machine learning tools to model each patient's disease trajectory.

Impact

We aim to develop biomarkers that enable the early identification of patients at risk of disease progression and predict their response to treatment, while also uncovering new therapeutic targets. The group has contributed to changing clinical practice in mechanical ventilation and pneumonia, coordinates the Spanish sarcoidosis registry and the European SARCOIDOMICS network, and leads projects funded by La Marató, the Instituto de Salud Carlos III (ISCIII), and the European Commission. The ultimate goal is to bring precision medicine to patients with severe lung diseases.